MarketPulse

obesity

7 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Zealand Pharma

Zealand Pharma Plants U.S. Flag in Cambridge with $M Research Hub by 2026

Zealand Pharma opens Cambridge research hub in September 2026 to expand AI-driven drug discovery and develop next-generation hybrid molecule therapeutics.
ZLDPYDOCpeptide therapeuticsobesity
BenzingaBenzinga··Vandana Singh

Embecta Expands Drug-Delivery Portfolio With $200M Owen Mumford Acquisition

Embecta to acquire UK firm Owen Mumford for up to $200M, bolstering drug-delivery capabilities and chronic care market reach. Stock rises 4.63%.
EMBCacquisitionM&A
GlobeNewswire Inc.GlobeNewswire Inc.··Biomea Fusion, Inc.

Biomea Fusion's Diabetes Drug Shows Durable Benefits Nine Months Post-Dose

Biomea Fusion presents positive Phase II data for icovamenib in type 2 diabetes, showing durable 1.2% HbA1c reduction nine months after dosing with favorable safety profile.
BMEAobesityType 2 diabetes
GlobeNewswire Inc.GlobeNewswire Inc.··Cadrenal Therapeutics, Inc.

Cadrenal's Novel 12-LOX Inhibitor Shows Promise in Obesity and Diabetes Research

Cadrenal's 12-LOX inhibitor CAD-1005 shows preclinical promise for obesity and diabetes inflammation reduction, potentially complementing GLP-1 medications.
CVKDclinical developmentGLP-1 medications
GlobeNewswire Inc.GlobeNewswire Inc.··Zealand Pharma

Zealand Pharma's Petrelintide Shows Promise in Obesity Drug Race

Zealand Pharma reports positive Phase 2 data for petrelintide, achieving 10.7% weight loss versus 1.7% placebo with favorable safety profile.
RHHBYZLDPYobesityweight management
GlobeNewswire Inc.GlobeNewswire Inc.··Roche

Roche's Weight-Loss Drug Shows Promise With Double-Digit Results in Phase II Trial

Roche's petrelintide demonstrates 10.7% weight reduction in Phase II, positioning the amylin analog as a potential alternative to dominant GLP-1 drugs with favorable tolerability. Phase III trials planned.
RHHBYZLDPYclinical resultsweight loss
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Anti-Snoring Device Market Poised to Double by 2033 Amid Health Awareness Surge

Global anti-snoring devices market projected to nearly double to $3.36 billion by 2033, driven by obesity, health awareness, and technological advances.
GSKRMDPHGe-commercemarket growth